Advertisement
U.S. markets close in 4 hours 56 minutes

iShares Biotechnology ETF (IBB)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
137.64-0.15 (-0.11%)
As of 11:03AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous Close137.79
Open138.40
Bid130.39 x 100
Ask145.49 x 100
Day's Range137.13 - 138.40
52 Week Range111.83 - 141.16
Volume301,108
Avg. Volume1,861,550
Net Assets7.64B
NAV137.78
PE Ratio (TTM)17.96
Yield0.25%
YTD Daily Total Return1.52%
Beta (5Y Monthly)0.79
Expense Ratio (net)0.45%
Inception Date2001-02-05
  • InvestorPlace

    3 Biotech ETFs Overdue for a Bounce

    Growth-focused investors may wish to set their sights on the hard-hit biotech stocks scene as rates begin to retreat, negative momentum settles and the industry catches a bit of a break for once. Of course, to get a higher chance at outsized gains, one must also have a high risk tolerance and a long-enough investment horizon. Also, when the tides get rough, one needs the confidence and conviction to hang on (or buy on dips). Indeed, the turbulent seas of the higher-growth corners of the biotech

  • InvestorPlace

    Biotechs on the Rise: 3 Stocks to Buy for a Shot of Profits

    If you’re looking for biotech stocks to buy, the iShares Biotechnology ETF (NASDAQ:IBB) is an excellent place to start. It tracks the performance of the ICE Biotechnology Index, a collection of U.S. companies in the biotech industry. But that exchange traded fund (ETF) hasn’t done well in recent years. In the past three years, its total return was 0.95% in 2021, -13.69% in 2022 and 3.76% in 2023. Year-to-date (YTD), it’s up 2.91%, considerably less than the 8.74% for the SPDR S&P 500 ETF Trust (

  • InvestorPlace

    Under the Microscope: 3 Biotech Stocks Pioneering Tomorrow’s Cures

    In the fluctuating U.S. stock market, biotech stocks have faced challenges. The sector’s most popular index, iShares Biotechnology ETF (NASDAQ:IBB), is dropping 9% year to date (YTD). Nevertheless, recent market developments point to a rebound on the horizon. It’s compelling investors to re-evaluate and hunt for the top biotech stocks offering robust upside potential ahead. Federal Reserve Chairman Jerome Powell’s hinting at potential rate cuts could spell a significant relief rally for biotech